TABLE 5.

Marketed Drug Products for AD recently approved by FDA.

Drug name (active)	Therapy	Company	Trial commencement	Type of clinical trial conducted for AD (trial ID)	Dosage form	References
Rexulti (Brexpiprazole)	Immunotherapy against Aβ aggregates	Otsuka	10 May 2023	Phase 3, multicenter,12-week, randomized, double-blind, placebo-controlled trial (NCT03548584)	Tablet for oral dose	Lee et al. (2023)
Leqembi (lecanemab-irmb)	Immunotherapy against Aβ aggregates	Biogen	6 July 2023	Phase 3, 18-month, multicenter, double-blind, trial (NCT03887455)	Injection for Intravenous Infusion	Practical Neurology (2023)
Aduhelm (Aducanumab)	Immunotherapy against Aβ aggregates	Biogen	7 June 2021	Two Phase 3, randomized, double-blind, placebo controlled (NCT02484547 and NCT02477800)	Injection for Intravenous Infusion	Budd Haeberlein et al. (2022)